• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Advisory Committees

  • Print
  • Share
  • E-mail

Briefing Information for the July 14, 2011 Meeting of the Oncologic Drugs Advisory Committee

 

Persons with disabilities having problems accessing the PDF file(s) below may call (301) 796-3634 for assistance
 
 
Morning Session:
 
FDA
 
Disclaimer
 
Portions of this document have been determined to be exempt from disclosure under the Freedom of Information Act (the FOIA) (5 U.S.C. § 552).
 
FDA Briefing Information, ADCETRIS (Brentuximab Vedotin) Injection – Hodgkin Lymphoma (HL), for the July 14, 2011 Meeting of the Oncologic Drugs Advisory Committee (PDF – 374KB)
 
Errata to the FDA Briefing Information, ADCETRIS (Brentuximab Vedotin) Injection – Hodgkin Lymphoma (HL), for the July 14, 2011 Meeting of the Oncologic Drugs Advisory Committee (PDF – 10KB)
 
 
Seattle Genetics, Inc
 
Disclaimer
 
The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.
 
Seattle Genetics Briefing Information, ADCETRIS (Brentuximab Vedotin) Injection – Hodgkin Lymphoma (HL), for the July 14, 2011 Meeting of the Oncologic Drugs Advisory Committee (PDF – 337KB)
 
Errata to the Seattle Genetics Briefing Information, ADCETRIS (Brentuximab Vedotin) Injection – Hodgkin Lymphoma (HL), for the July 14, 2011 Meeting of the Oncologic Drugs Advisory Committee (PDF – 17KB)
 
Afternoon Session:
 
FDA
 
Disclaimer
 
Portions of this document have been determined to be exempt from disclosure under the Freedom of Information Act (the FOIA) (5 U.S.C. § 552).
 
FDA Briefing Information, ADCETRIS (Brentuximab Vedotin) Injection – Anaplastic Large Cell Lymphoma (ALCL), for the July 14, 2011 Meeting of the Oncologic Drugs Advisory Committee (PDF – 318KB)
 
Errata #1 to the FDA Briefing Information, ADCETRIS (Brentuximab Vedotin) Injection – Anaplastic Large Cell Lymphoma (ALCL), for the July 14, 2011 Meeting of the Oncologic Drugs Advisory Committee (PDF – 9KB)
 
Errata #2 to the FDA Briefing Information, ADCETRIS (Brentuximab Vedotin) Injection – Anaplastic Large Cell Lymphoma (ALCL), for the July 14, 2011 Meeting of the Oncologic Drugs Advisory Committee (PDF – 17KB)
 
 
Seattle Genetics, Inc
 
Disclaimer
 
The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.
 
Seattle Genetics Briefing Information, ADCETRIS (Brentuximab Vedotin) Injection – Anaplastic Large Cell Lymphoma (ALCL), for the July 14, 2011 Meeting of the Oncologic Drugs Advisory Committee (PDF – 330KB)